Delusional disorders in dermatology: A brief review

Dermatology Online Journal

Volumn 14, Issue 6, 2008, Pages

  Robles, David T ^a   Romm, Sharon ^a   Combs, Heidi ^a   Olson, Jonathan ^a   Kirby, Phil ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PIMOZIDE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ARTICLE; AUTOMUTILATION; BODY DYSMORPHIC DISORDER; CLINICAL FEATURE; COGNITIVE THERAPY; COMPULSION; DELUSION OF PARASITOSIS; DELUSIONAL DISORDER; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISTRESS SYNDROME; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GROUP THERAPY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; MORGELLON DISEASE; OLFACTORY REFERENCE SYNDROME; PARASITOSIS; QT PROLONGATION; RITUAL; SIDE EFFECT; SOCIAL ISOLATION; SUDDEN DEATH; SUICIDE; SYMPTOM; TARDIVE DYSKINESIA; DERMATOLOGY; METHODOLOGY; PREVALENCE; PSYCHOLOGICAL ASPECT; REVIEW; SKIN DISEASE; SOMATOFORM DISORDER;

ANTIPSYCHOTIC AGENTS; DERMATOLOGY; HUMANS; PREVALENCE; SKIN DISEASES; SOMATOFORM DISORDERS;

EID: 46449104113     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Koo J, Lebwohl A: Psycho dermatology: the mind and skin connection. Am Fam Physician 2001; 64(11): 1873-8.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC, 2000.
3. The matchbox sign. Lancet 1983; 2(8344): 261.
4. Koo J, Lee CS: Delusions of parasitosis. A dermatologist's guide to diagnosis and treatment. Am J Clin Dermatol 2001; 2(5): 285-90.
5. Walling HW, Swick BL: Psychocutaneous syndromes: a call for revised nomenclature. Clin Exp Dermatol 2007; 32(3): 317-9.
6. van Vloten WA: Pimozide: use in dermatology. Dermatol Online J 2003; 9 (2): 3.
7. Donabedian H: Delusions of Parasitosis. Clin Infect Dis 2007; 45(11).
8. Wenning MT, Davy LE, Catalano G, Catalano MC: Atypical antipsychotics in the treatment of delusional parasitosis. Ann Clin Psychiatry 2003; 15(3-4): 233-9.
9. Szepietowski JC, Salomon J, Hrehorow E, Pacan P, Zalewska A, Sysa-Jedrzejowska A: Delusional parasitosis in dermatological practice. J Eur Acad Dermatol Venereol 2007; 21(4): 462-5.
10. Zomer SF, De Wit RF, Van Bronswijk JE, Nabarro G, Van Vloten WA: Delusions of parasitosis. A psychiatric disorder to be treated by dermatologists? An analysis of 33 patients. Br J Dermatol 1998; 138(6): 1030-2.
11. Elmer KB, George RM, Peterson K: Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 2000; 43(4): 683-6.
12. Lorenzo CR, Koo J: Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol 2004; 5(5): 339-49.
13. Meehan WJ, Badreshia S, Mackley CL: Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol 2006; 142(3): 352-5.
14. Mercan S, Altunay IK, Taskintuna N, Ogutcen O, Kayaoglu S: Atypical antipsychotic drugs in the treatment of delusional parasitosis. Int J Psychiatry Med 2007; 37(1): 29-37.
15. Freudenmann RW, Schonfeldt-Lecuona C, Lepping P: Primary delusional parasitosis treated with olanzapine. Int Psychogeriatr 2007; 19(6): 1161-8.
16. De Leon OA, Furmaga KM, Canterbury AL, Bailey LG: Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997; 27(4): 403-9.
17. Friedmann AC, Ekeowa-Anderson A, Taylor R, Bewley A: Delusional parasitosis presenting as folie a trois: successful treatment with risperidone. Br J Dermatol 2006; 155(4): 841-2.
18. Koblenzer CS: The challenge of Morgellons disease. J Am Acad Dermatol 2006; 55(5): 920-2.
19. Savely VR, Leitao MM, Stricker RB: The mystery of Morgellons disease: infection or delusion? Am J Clin Dermatol 2006; 7(1): 1-5.
20. Murase JE, Wu JJ, Koo J: Morgellons disease: a rapport-enhancing term for delusions of parasitosis. J Am Acad Dermatol 2006; 55(5): 913-4.
21. Koblenzer CS: Pimozide at least as safe and perhaps more effective than olanzapine for treatment of Morgellons disease. Arch Dermatol 2006; 142 (10): 1364.
22. Cororve MB, Gleaves DH: Body dysmorphic disorder: a review of conceptualizations, assessment, and treatment strategies. Clin Psychol Rev 2001; 21(6): 949-70.
23. Veale D: Body dysmorphic disorder. Postgrad Med J 2004; 80(940): 67-71.
24. Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB: Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry 2005; 66(6): 717-25.
25. Castle DJ, Phillips KA, Dufresne RG, Jr.: Body dysmorphic disorder and cosmetic dermatology: more than skin deep. J Cosmet Dermatol 2004; 3 (2): 99-103.
26. Patterson WM, Bienvenu OJ, Chodynicki MP, Janniger CK, Schwartz RA: Body dysmorphic disorder. Int J Dermatol 2001; 40(11): 688-90.
27. Jakubietz M, Jakubietz RJ, Kloss DF, Gruenert JJ: Body dysmorphic disorder: diagnosis and approach. Plast Reconstr Surg 2007; 119(6): 1924-30.
28. Bowe WP, Leyden JJ, Crerand CE, Sarwer DB, Margolis DJ: Body dysmorphic disorder symptoms among patients with acne vulgaris. J Am Acad Dermatol 2007; 57(2): 222-30.
29. Phillips KA, Menard W, Fay C: Gender similarities and differences in 200 individuals with body dysmorphic disorder. Compr Psychiatry 2006; 47 (2): 77-87.
30. Crerand CE, Franklin ME, Sarwer DB: Body dysmorphic disorder and cosmetic surgery. Plast Reconstr Surg 2006; 118(7): 167e-80e.
31. Hunter-Yates J, Dufresne RG, Jr., Phillips KA: Tanning in body dysmorphic disorder. J Am Acad Dermatol 2007; 56(5 Suppl): S107-9.
32. Mackley CL: Body dysmorphic disorder. Dermatol Surg 2005; 31(5): 553-8.
33. Phillips KA, Albertini RS, Rasmussen SA: A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002; 59(4): 381-8.
34. Phillips KA: Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr 2002; 7(6): 453-60, 463.
35. Sumathipala A: What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007; 69(9): 889-900.
36. Stein DJ, Le Roux L, Bouwer C, Van Heerden B: Is olfactory reference syndrome an obsessive-compulsive spectrum disorder?: two cases and a discussion. J Neuropsychiatry Clin Neurosci 1998; 10(1): 96-9.
37. Lochner C, Stein DJ: Olfactory reference syndrome: diagnostic criteria and differential diagnosis. J Postgrad Med 2003; 49(4): 328-31.
38. Devinsky O, Khan S, Alper K: Olfactory reference syndrome in a patient with partial epilepsy. Neuropsychiatry Neuropsychol Behav Neurol 1998; 11 (2): 103-5.
39. Pryse-Phillips W: An olfactory reference syndrome. Acta Psychiatr Scand 1971; 47(4): 484-509.
40. Dominguez RA, Puig A: Olfactory reference syndrome responds to clomipramine but not fluoxetine: a case report. J Clin Psychiatry 1997; 58 (11): 497-8.
41. Kizu A, Miyoshi N, Yoshida Y, Miyagishi T: A case with fear of emitting body odour resulted in successful treatment with clomipramine. Hokkaido Igaku Zasshi 1994; 69(6): 1477-80.
42. Brotman AW, Jenike MA: Monosymptomatic hypochondriasis treated with tricyclic antidepressants. Am J Psychiatry 1984; 141(12): 1608-9.